Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted price/coverage claims are not supported by the FDA-approved prescribing information; no label-consistent content present.
Category Scores
Accurate Statements
Unsupported Statements
Generic atorvastatin prices vary a lot by dose (10 mg vs 20 mg vs 40 mg vs 80 mg), tablet count, and pharmacy.
Not present in prescribing information; pricing/availability details are not part of FDA-approved label.
Commonly, a 30- or 90-day supply at major retail pharmacies can range from “a few dollars” to “around a couple dozen dollars” when paying cash.
Not present in prescribing information; price ranges and cash-pay specifics are not part of FDA-approved label.
Lower pricing is often available through discount programs.
Not present in prescribing information; discount program details are not part of FDA-approved label.
Pharmacy discount programs are often cheaper than the pharmacy’s listed cash price.
Not present in prescribing information; comparisons to cash prices are not part of FDA-approved label.
Manufacturer or plan discounts are available where available.
Not present in prescribing information; discount availability is not part of FDA-approved label.
Using a 90-day supply instead of 30 days.
Not present in prescribing information; 90-day supply details are not part of FDA-approved label.
Checking whether your prescription matches the generic strength and quantity (sometimes costs jump with higher doses like 80 mg).
Not present in prescribing information; cost considerations for strength/quantity are not part of FDA-approved label.
The dose is higher (e.g., 80 mg).
Not present in prescribing information; dosing details are in the label, but this statement concerns pricing context rather than labeling content.
The prescription is for a larger tablet count (e.g., 90-day supply).
Not present in prescribing information; dispensing quantity details are not part of FDA-approved label.
Using brand-name atorvastatin instead of generic is much more expensive.
Not present in prescribing information; brand/generic cost comparisons are not part of FDA-approved label.
Insurance coverage rules require a specific formulation or pharmacy.
Not present in prescribing information; insurance/formulary rules are not part of FDA-approved label.
With insurance, your 'cost' usually means your copay.
Not present in prescribing information; insurance cost details are not part of FDA-approved label.
Copay depends on your plan’s formulary tier for atorvastatin.
Not present in prescribing information; formulary tier details are not part of FDA-approved label.
Copay depends on whether you use a preferred pharmacy.
Not present in prescribing information; pharmacy preference is not part of FDA-approved label.
Copay depends on whether the claim is filled as a specific generic NDC/strength.
Not present in prescribing information; NDC/strength-specific copay details are not part of FDA-approved label.
The lowest price usually comes from comparing your local pharmacy’s cash price.
Not present in prescribing information; cash price comparisons are not part of FDA-approved label.
Discount card price is often accessible at pickup time.
Not present in prescribing information; discount card details are not part of FDA-approved label.
Prices online or through mail-order are options for a 90-day supply.
Not present in prescribing information; mail-order/online pricing for a 90-day supply is not part of FDA-approved label.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Pricing/coverage claims do not directly impact patient safety in the context of the FDA label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Pricing/insurance claims are not supported by the FDA-approved prescribing information.
Suggested Improvement
Limit content to FDA-labeled prescribing information (indication, dosage, administration, contraindications, warnings/precautions, interactions, use in specific populations, adverse reactions, and storage) and avoid non-label pricing or coverage details.